The private investment fund Phimie, which manages about $ 5.5 billion and acquires control of companies to carry out improvement processes, announces that it has completed the acquisition of the Rafa pharmaceutical company. According to the report, the fund purchased 88% of the pharmaceutical company’s shares for NIS 540 million. The Levin family, of the current shareholders, will hold the remaining shares.
Rafa Laboratories Ltd., founded in 1937 by the late Dr. Baruch Levin, employs about 300 workers, and is owned by the Sackler family, the Levin family and the Reshef family. The company specializes in development, production, marketing, and distribution. Of source drugs and generic drugs, prescription drugs and over-the-counter drugs as well as therapeutic products and its products are marketed to all health institutions in Israel, including: public and private hospitals, clinics, health funds, pharma chains and other entities.The main areas of operation are gastroenterology, respiratory diseases. And palliative care.
According to the report, another significant area of the company is the area of automatic syringes. The company is an exclusive supplier to the Department of Defense, the U.S. and other countries to which it supplies automated syringes that contain drugs against exposure to chemical weapons (such as nerve gas), and collaborates with leading companies in the world, such as UTHR, Mundipharma, Galderma, Takeda, AstraZeneca, Dr. Falk Pharma, Helsinn et al.
Two days ago, Phimie announced that Simploa, a company controlled by her (67%), also belongs to
The Phoenix
+ 1.12%
Base:2,315
opening:2,341
Tall:0
low:0
change:–
Page Quote News Graphs Company Profile Recommendations
More articles on the subject:
And Leumi Partners (33%), acquired 70% of Novamed at a value of about NIS 24 million (for the full article).
The Phimie Fund is a private equity fund with assets under management of approximately $ 5.5 billion. Investors in Pimi funds are about 50% foreign, which includes some of the largest institutional and private entities in the world, including banks, state-owned funds, insurance companies, pension funds, universities, world-leading private investors, international giants and more, and about 50% Israelis, including Banks, insurance companies, large and leading institutional bodies in Israel, universities, private investors and more.
The fund acquires control of companies and implements improvement processes in them. To date, the fund has acquired control of about 93 companies and has realized about 63 of them in a volume of transactions of more than $ 5.5 billion. The fund employs more than 30,000 people and operates in about 50 factories in Israel and another 100 factories and companies around the world.
Phimie invests in Israeli companies and companies that have an affinity for Israel and has to date invested in companies such as Retalix, Rivlis, Novolog, Magal, Hamlet, Tami 4, Ormat, Ofir, Scoop, Medtechnika, Hamat, Gilat Satellite Systems, Metro Motor, Tat Technologies, Ordan, Aloni , Itung, Carmit, Nirlat, Tadiran Kesher, Lipman, Formula Systems, Orian, Rebel, Priortech, Solver, Dimmer, Givon, H. Mr., Overseas, Hadera Paper, Oxygen and Organization plants, Polyram, Unitronics, Galam, Delek-San, G1 Security Systems, BIRD, Orbit, SOS Energy, Simplia, Stern, ImageSat, Aitech Kamhada, Rimoni, Ben Ari, Rafa and more.